Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV1)  is pleased to inform investors that it is among the set of applicants to have recently been contacted by Health Canada. The Company’s application to produce cannabis under the ‘Access to Cannabis for Medical Purposes Regulations’ (ACMPR) in Canada is currently in ‘Active Review’. The Company is in the process of upgrading its Delta facility to meet the requirements of the ACMPR, which have changed since the Company’s original application under the ‘Marihuana for Medical Purposes Regulations’ (MMPR). These updates include minor hardware upgrades to its video surveillance and intrusion detection systems and installation of a seed-to-sale tracking system. Vodis plans to select Canadian-made Ample Organics as its seed-to-sale tracking system provider.
Vodis is also pleased to announce that the expansion to its facility in Bellingham, WA, announced March 23, 2017, is approximately 75% complete. This work involved major structural changes to the building to support the construction of a 2nd floor within the facility above previously licensed, unused, canopy space. At present the completed work will allow the Company’s tenant, Premium Cannabis Producers LLC (“PCP”), to double its current production capacity. Upon completion, the facility will support the full 10,000 sq ft of PCP’s Tier 2 license capacity. The Company anticipates the Bellingham expansion to be complete before the end of the year.
This news release shall not constitute an offer to sell or solicitation of an offer to buy the securities in any jurisdiction. The securities will not be and have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirements.
About Vodis Pharmaceuticals Inc.
Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada. Its master grow teams have consistently won or placed at each Canadian competition they have entered with their “VIP” brand. The Company, with facilities in British Columbia and Washington State, is also actively looking into expansion opportunities in other countries and throughout the United States.
For further information, please contact:
Ivan Miliovski, CEO
Vodis Pharmaceuticals Inc.
1-866-210-1420 Ext103
-or-
Soy Garipoglu
Investor Relations
Vodis Pharmaceuticals Inc.
8788 River Road
Delta, BC V4G 1B4
Contact: 778-990-8985
Email: investorrelations@vodis.ca
Web: www.vodis.ca
Forward-Looking Information: This news release contains certain forward-looking information that reflects the current views and/or expectations of the Company with respect to its performance, business and future events. Forward-looking information is based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. Statements constituting forward-looking information are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Investors are cautioned that all forward-looking information involves risks and uncertainties, which could cause actual results and events to vary significantly. Accordingly, readers should not place undue reliance on forward-looking information, which is qualified in their entirety by this cautionary statement. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward-looking information, will prove to be accurate. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking information, except as required by applicable securities law.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
Not for distribution to United States newswire services or for dissemination in the United States
Click here to connect with Vodis Pharmaceuticals Inc. (CSE:VP,FSE:1JV1) to receive an Investor Presentation.

Source: www.thenewswire.com


American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less